

## XP-002097957

1/1 - (C) WPI / DERWENT  
AN - 89-019644 ç25!  
AP - JP870129551 870526  
PR - JP870129551 870526  
TI - Enteric anticoagulation thrombolytic drug - contains  
protease with plasminogen activator activity, having  
low toxicity etc.  
IW - ENTERAL ANTICOAGULANT THROMBOLYTIC DRUG CONTAIN  
PROTEASE PLASMINOGEN ACTIVATE ACTIVE LOW TOXIC  
PA - (KAOS ) KAO CORP  
PN - JP63295515 A 881201 DW8903 004pp  
ORD - 1988-12-01  
IC - A61K37/54  
FS - CPI  
DC - B04 D16  
AB - J63295515 An anticoagulation thrombolytic drug contains  
as active ingredient a protease having plasminogen  
activator activity.  
- The protease having plasminogen activator activity is  
e.g. prourokinase, tissue plasminogen activator,  
trypsin, kallikrein, thrombin, bromelain, etc.. Enteric  
coating is e.g. of ethyl acrylate/methacrylic acid  
copolymer, hydroxypropyl methyllose cellulose acetate  
succinate, etc. The dose may be 50,00 to 200,000  
urokinase units per day for adult.  
- USE/ADVANTAGE - The protease can be easily administered  
orally with good effect, and has low toxicity and side  
effects.